Head-to-head · Value Score
CoreAge Rx vs Invyncible
Two GLP-1 deals, scored on the same six factors. CoreAge Rx lands a Value Score of 93, Invyncible a 68. Here's who gives you the honest lower price — and where each one bites back.
CoreAge Rx
#1 · Grade A+ · Best Value
Est. first month
$149/mo
Save ~89% vs brand-nameInvyncible
#279 · Grade C · Watch List
Est. first month
From $192/mo (starting dose, compounded)
Save ~86% vs brand-nameThe verdict
CoreAge Rx takes it on Value Score, 93 to 68 — an est. $149/mo first month, with no teaser step-up baked in. Invyncible isn't out of it: Shoppers who want corporate-parent-disclosed Florida GLP-1 platform with LegitScript seal.
CoreAge Rx is also our overall #1 pick across the whole deals board — a flat, all-in price on both molecules in all 50 states. That's why it wins here on the score, not just this matchup.
Deal-by-deal
The numbers that decide it. Green ✓ marks the stronger side on each line.
| Deal | CoreAge Rx | Invyncible |
|---|---|---|
| Value Score | 93 (A+) | 68 (C) |
| Est. first month | $149/mo | From $192/mo (starting dose, compounded) |
| Save vs brand-name | ~89% | ~86% |
| Semaglutide | $149/mo | From $192/mo (starting dose, compounded) |
| Tirzepatide | $349/mo | From $210/mo (compounded) |
| Both molecules | Yes | Yes |
| Pricing | Flat — no step-up | Watch |
| Coverage | All 50 states | 40 states |
Factor by factor
The six factors behind each Value Score. The orange bar marks the stronger side. See the methodology.
CoreAge Rx
The honest lowest price: both molecules at one flat, all-in monthly rate that never steps up after month one.
Why it's a deal
- Flat, all-in monthly price with no intro-rate step-ups after month one
- Both compounded semaglutide and tirzepatide on one account
- Available in all 50 states
- Straightforward, low-friction cancellation — no lock-in
The fine print
- Not the rock-bottom sticker — a couple of teaser tiers advertise lower month-one rates
- No FDA-approved brand-name option (compounded only)
- Does not yet publicly name its 503A/B pharmacy partner
Invyncible
Invyncible is a Florida-based telehealth platform offering semaglutide and tirzepatide programs for weight management.
Why it's a deal
- Corporate parent disclosed (Nationwide Telemedicine, LLC) — better than most competitors hiding behind trade names
- Physical corporate address published (St. Petersburg, FL)
- LegitScript verification seal displayed
- No long-term commitment required
- Offers both semaglutide and tirzepatide programs
The fine print
- Pricing not disclosed on the public site — fully gated behind signup
- Drug forms (compounded vs brand, injection vs oral) not disclosed
- 503A vs 503B designation not specified
- Pharmacy partner not named
- States served not listed publicly
Assume any provider we list may compensate us — we may earn a commission, at no cost to you. It never changes a Value Score.
Neither one the right fit? Every program that outscores CoreAge Rx is ranked on the CoreAge Rx alternatives board, and the same list for the other side is on alternatives to Invyncible.
More head-to-heads
Prices, states and verification reflect each program's public disclosures at last check; the Value Score is our editorial judgment per the methodology. “Save vs brand-name” compares the lowest disclosed monthly price against a ~$1,349/mo brand-name cash reference. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.